Soybean (ZS)

Dernières nouvelles pour Zscaler (NASDAQ:ZS) Stock

Zscaler

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

Zscaler Inc

USCF ETF Trust USCF Sustainable Battery Metals Strategy Fund

USCF ETF Trust USCF Sustainable Commodity Strategy Fund

Innovator Equity Defined Protection ETF - 1 Yr September

ZHONGSHENG GP HL UNSP/ADR by Zhongsheng Group Holdings Ltd

Zhongsheng Group Holdings Ltd

ZENSHO HLDGS CO LTD by ZENSHO HLDGS CO LTD

Zensho Holdings Co Ltd

ZKB SILVER ETF ETF

ProShares UltraShort Silver

Zhong Shi International Ltd

BMO S&P US SMALL CAP INDEX ETF

BMO S&P 500 INDEX USD UNT ETF

ZSPACE Inc

zSpace Technologies, Inc

Diamond Water Origin Supply Chain Technology Group Co Ltd

ZSTAR ENTERPRISES INC by ZST Digital Networks, Inc.

ZST Digital Networks Inc

Smart Closet Inc

ZSCALER ORD

One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) raises FY2024 sales outlook from $700.00 million-740.00 million to $844.00 million-864.00 million.

News

Guidance

STKS

One Group Hospitality Raises FY2024 Sales Guidance from $700.00M-740.00M to $844.00M-864.00M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

ADPT

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year.

Earnings

Earnings Misses

RGLS

Regulus Therapeutics Q3 EPS $(0.21) Misses $(0.17) Estimate

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/b41823677/affirm-reports-first-fiscal-quarter-2025-results">figures from the quarter.   </a>
The Details: Affirm reported quarterly losses of 31 cents per share, which beat the analyst consensus estimate for losses of 35 cents. Quarterly revenue came in at $698.47 million which beat the analyst consensus estimate of $664.01 million and is an increase over sales of $496.54 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We continued driving accelerated growth while delivering consistent credit outcomes and managing the business to our target of 3-4% RLTC as a percentage of GMV, which stood at 3.8% this quarter. Year-over-year GMV growth re-accelerated, and growth in active consumers accelerated for the third consecutive quarter,&#8221; said Max Levchin, Affirm&#8217;s CEO.
&#8220;Transactions per active consumer grew 25% year over year to 5.1, and trailing 12-month GMV per active consumer grew 11% year over year to $1,500. We continue to expect to reach GAAP Operating Income profitability in FQ4'25,&#8221; Levchin added.
Outlook:&nbsp;Affirm sees second-quarter revenue of between $770 million and $810 million and fiscal year 2025 GMV of more than $34 billion. 
AFRM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affirm shares are down 0.71% after-hours at $48.45 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Movers

AFRM

Affirm Reports Better-Than-Expected Q1 Results: Details

WIIM

INOD

Innodata shares are trading higher after the company reported better-than-expected Q3 financial results.

Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.65) by 33.85 percent. The company reported quarterly sales of $948.600 million which missed the analyst consensus estimate of $956.789 million by 0.86 percent. This is a 6.63 percent decrease over sales of $1.016 billion the same period last year.

Earnings Beats

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Lions Gate Entertainment Corporation Class B Non-Voting Shares Q2 2025 Adj. EPS $(0.43) Beats $(0.65) Estimate, Sales $948.600M Miss $956.789M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $648.50 thousand by 234.62 percent. This is a 134.85 percent increase over sales of $924.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.64) by 117.19 percent. This is a 208.89 percent decrease over losses of $(0.45) per share from the same period last year.

ETNB

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

Agilon Health shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 60 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $641.141 thousand which beat the analyst consensus estimate of $375.000 thousand by 70.97 percent. This is a 73.91 percent decrease over sales of $2.457 million the same period last year.

CODX

Co-Diagnostics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $641.141K Beat $375.000K Estimate

ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $171.33 million which beat the analyst consensus estimate of $160.42 million by 6.80 percent. This is a 43.96 percent increase over sales of $119.01 million the same period last year.

ACVA

ACV Auctions Q3 EPS $(0.10) Beats $(0.11) Estimate, Sales $171.33M Beat $160.42M Estimate

Retail Sales

PRCH

Porch Group Announced That It Lowered Its FY24 Sales Guidance From $450M-470M to $440M-455M

SGHT

Sight Sciences Sees FY24 Revenue $81M-$83M Vs $82.16M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) raises FY2024 sales outlook from $318.00 million-325.00 million to $322.00 million-326.00 million.

Eventbrite Raises FY2024 Sales Guidance from $318.00M-325.00M to $322.00M-326.00M  VS Est.322.03M

Stock Split

ANET

Arista Approved Four-For-One Forward Stock Split

RIGL

Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $231.358 million which beat the analyst consensus estimate of $223.537 million by 3.50 percent. This is a 5.44 percent increase over sales of $219.419 million the same period last year.

CARG

CarGurus Q3 2024 Adj. EPS $0.45 Beats $0.42 Estimate, Sales $231.358M Beat $223.537M Estimate

ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively.

ADMA

ADMA Biologics FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively

BSLK

Bolt Projects Holdings Q3 EPS $0.32

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Jefferies analyst Joseph Gallo maintained a Buy rating on Zscaler (ZS – Research Report) today and set a price target of $225.00. The company's sha...

Zscaler (ZS): New Buy Recommendation for This Technology Giant

Zscaler says its cloud security platform crosses half a trillion daily transactions

Fortinet products enjoy healthy demand on recent checks: TD Cowen

Cyberattacks are on the rise in the wake of a digitalized world fueled by AI

Wolfe's tax loss selling stocks within industrials, tech, materials

Cloudflare Stock Has Further To Run On Revenue, Margin Improvement

Cloudflare, Fortinet show strong uptick in Q3 as per Wells Fargo's cybersecurity reseller survey

Software overweight positions hits lowest rate ever in Jefferies' survey

Tenable, Fortinet seen as 'well positioned' to benefit from federal spending: Baird

Qualys surges on strong quarter, but will results continue?

ADBE

AGCO

ALGM

ATKR

BILL

BRZE

CFLT

CHKP

CIBR

CLVT

CNXC

CRWD

CYBR

DDOG

EPAM

FIVN

FRSH

FTNT

GTLB

GTLS

HACK

IGPT

IHAK

INTC

IPGP

LSCC

MSFT

OKTA

ORCL

PANW

PATH

PAYC

PLTR

POWI

PYCR

QLYS

SEDG

SIRI

SNAP

SNOW

SPAM

TEAM

TENB

UCYB

WCBR

WDAY

WOLF

Press Releases

Zscaler to Present at Upcoming Investor Conferences

Zscaler Reports Fourth Quarter and Fiscal 2024 Financial Results

General

Zscaler and CrowdStrike Announce New AI and Zero Trust Cybersecurity Integrations

Management

Zscaler Appoints Security Industry Veteran Adam Geller as Chief Product Officer to Scale Cloud Security Leader to $5 Billion ARR and Beyond

Zscaler Zero Trust Exchange™ Extends Cybersecurity Market Leadership by Surpassing Half a Trillion Daily Transactions

Global Cybersecurity Becoming Increasingly Vital as Market Revenues are Now Part of a Multi-Billion Dollar Industry Opportunity

Zscaler Identifies More Than 200 Malicious Apps in the Google Play Store, with Over 8 Million Installs

Zscaler and Okta Enhance Enterprise Cybersecurity with New Zero Trust Integrations

Opinion

1 Billion Records Stolen in 2024: How Cutting-Edge Tech Is Fighting Back Against Cybercrime

Comments

Zscaler

Actualités

Dernières nouvelles pour Zscaler (NASDAQ:ZS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL